James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland.
James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland.
J Urol. 2016 Oct;196(4):989-99. doi: 10.1016/j.juro.2016.04.081. Epub 2016 May 6.
Several options exist for management of clinically localized renal masses suspicious for cancer, including active surveillance, thermal ablation and radical or partial nephrectomy. We summarize evidence on effectiveness and comparative effectiveness of these treatment approaches for patients with a renal mass suspicious for localized renal cell carcinoma.
We searched MEDLINE®, Embase® and the Cochrane Central Register of Controlled Trials from January 1, 1997 through May 1, 2015. Paired investigators independently screened articles to identify controlled studies of management options or cohort studies of active surveillance, abstracted data sequentially and assessed risk of bias independently. Strength of evidence was graded by comparisons.
The search identified 107 studies (majority T1, no active surveillance or thermal ablation stratified outcomes of T2 tumors). Cancer specific survival was excellent among all management strategies (median 5-year survival 95%). Local recurrence-free survival was inferior for thermal ablation with 1 treatment but reached equivalence to other modalities after multiple treatments. Overall survival rates were similar among management strategies and varied with age and comorbidity. End-stage renal disease rates were low for all strategies (0.4% to 2.8%). Radical nephrectomy was associated with the largest decrease in estimated glomerular filtration rate and highest incidence of chronic kidney disease. Thermal ablation offered the most favorable perioperative outcomes. Partial nephrectomy showed the highest rates of urological complications but overall rates of minor/major complications were similar among interventions. Strength of evidence was moderate, low and insufficient for 11, 22 and 30 domains, respectively.
Comparative studies demonstrated similar cancer specific survival across management strategies, with some differences in renal functional outcomes, perioperative outcomes and postoperative harms that should be considered when choosing a management strategy.
对于疑似癌症的局部肾肿瘤,有几种治疗选择,包括主动监测、热消融和根治性或部分肾切除术。我们总结了这些治疗方法对局部肾细胞癌可疑肾肿块患者的有效性和比较有效性的证据。
我们检索了 MEDLINE、Embase 和 Cochrane 中央对照试验注册库,检索时间为 1997 年 1 月 1 日至 2015 年 5 月 1 日。配对的调查员独立筛选文章,以确定管理方案的对照研究或主动监测的队列研究,依次提取数据并独立评估偏倚风险。通过比较来分级证据的强度。
搜索结果共发现 107 项研究(多数为 T1 期,无主动监测或热消融分层 T2 期肿瘤的结果)。所有治疗策略的癌症特异性生存率均很高(中位 5 年生存率为 95%)。热消融治疗 1 次后局部无复发生存率较差,但多次治疗后达到与其他治疗方法相当的水平。不同治疗策略的总生存率相似,并且因年龄和合并症而异。所有治疗策略的终末期肾病发生率均较低(0.4%至 2.8%)。根治性肾切除术与估计肾小球滤过率下降幅度最大和慢性肾脏病发生率最高相关。热消融术具有最有利的围手术期结局。部分肾切除术显示出最高的尿路上皮并发症发生率,但各种干预措施的轻微/严重并发症发生率相似。证据强度分别为中度、低度和不足 11、22 和 30 个领域。
比较研究表明,不同治疗策略的癌症特异性生存率相似,但在肾功能结局、围手术期结局和术后危害方面存在差异,在选择治疗策略时应考虑这些差异。